Alicia K. Morgans, MD, MPH

Alicia K. Morgans, MD, MPH

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chicago, Illinois

Alicia K. Morgans is an Associate Professor of Medicine (Hematology and Oncology) at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine in Chicago, where she provides clinical care and does research in genitourinary malignancies. Dr. Morgans received her MD from the University of Pennsylvania in 2006. She then completed her internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania in 2009, and her fellowship in Hematology-Oncology at the Dana-Farber Cancer Institute in 2012. In 2015, Dr. Morgans received her MPH from Vanderbilt University School of Medicine. Since 2004, her work on a myriad of important uro-oncological topics has been included in such publications as Urology, European Urology, Prostate, and Cancer Medicine. She is also on the Editorial Board of the Journal of Clinical Oncology. Additionally, she is currently leading three active clinical trials.

Talks by Alicia K. Morgans, MD, MPH

Recognizing and Managing the Side Effects of Androgen Deprivation Therapy

Recognizing and Managing the Side Effects of Androgen Deprivation Therapy

Posted by | Apr 2020

Alicia K. Morgans, MD, MPH, Associate Professor of Medicine in Hematology and Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the side effects of androgen deprivation therapy (ADT) and how urologists can mitigate them. She observes that up to 40% of non-metastatic prostate cancer patients are treated with ADT, and those patients tend to be older and have more comorbidities. Studies have suggested that comorbidities and advanced age interact with ADT to increase risk of cardiovascular disease and diabetes. ADT is also associated with increased risk of depression, cognitive changes, and possibly dementia, as well as greater frailty in patients. Urologists should be aware of these side effects so that they can assess their patients’ risk and plan accordingly with multidisciplinary teams to reduce mortality and morbidity and improve quality of life.

Read More
M0 CRPC: Treatment Options and Emerging Concepts

M0 CRPC: Treatment Options and Emerging Concepts

Posted by | Mar 2020

Alicia K. Morgans, MD, MPH, Associate Professor of Medicine in Hematology and Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the use of androgen receptor antagonists in treating patients with non-metastatic (M0) castrate-resistant prostate cancer (CRPC). She goes on to discuss how before these three pivotal trials, treatment for patients with M0 CRPC remained a bit of a mystery. However, the results of these trials demonstrated treating men with these agents who had a PSA doubling time less than ten months significantly improved their metastasis-free survival compared to men in the control arm.

Read More

Join the GRU Community

- Why Join? -